Innovent Biologics Adds $25 Million to Expand its Antibody Pipeline and its Manufacturing Capabilities

Suzhou, China, (PresseBox) - B3C newswire / -Innovent Biologics, Inc., a company dedicated to the development and manufacturing of monoclonal antibodies to be marketed in the rapidly growing China market and elsewhere around the world, has raised $25 Million in a Series B financing to put toward the continued expansion of its pipeline and manufacturing capabilities. The money comes from Lilly Asia Ventures, part of the innovative global pharmaceutical company Eli Lilly, and from Fidelity Biosciences and Fidelity Growth Partners Asia, a division of Fidelity, one of the world's leading financial services companies. Fidelity is a follow-on investor from the Series A.

"We are fortunate to have world's premier investors believing in our team and business. Biologics are going to be a huge category in China just as they are worldwide, which presents a unique, once in a lifetime opportunity. Innovent has positioned itself to be a leading biologics company in China", Said Michael Yu, Ph.D., Co-founder, President and CEO of Innovent Biologics.

The team at Innovent brings extensive experience in the discovery, development and manufacture of biologics in the US, Europe and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Humira, Natrecor, Oncorine, Orencia, and others.

Innovent has a GMP-compliant pilot plant for the production of clinical trial material and is building a new campus located in Suzhou near Shanghai China. In addition to laboratories and offices, the campus will house a commercial manufacturing plant with multiple 12,000 L bioreactors and a pilot plant, with two 1000L bioreactors, for production of clinical materials. The 90,000m2 biopharmaceutical facility will be the largest biologics production facility in China designed to comply with international requirements for cGMP as defined by the European EMA and the US FDA, as well as meet China SFDA cGMP regulations.

Companies who want to leverage the Innovent commitment to bring quality manufacturing and development to the expanding China biologics market have helped Innovent begin building a pipeline of biologics. The pipeline currently includes a CD20 antibody for Non-Hodgkins Lymphoma (NHL) and other B cell mediated diseases, a bispecific antibody for cancer and an antibody for oncology. Innovent continues to actively seek product candidates for in-licensing and co-development.

For more information about Innovent, see www.InnoventBio.com

Press releases you might also be interested in

Weitere Informationen zum Thema "Biotechnik":

Intel zeigt Ausblick auf die künstliche Intelligenz von morgen

Wel­che Ve­r­än­de­run­gen, die künst­li­che In­tel­li­genz zu­künf­tig für uns al­le brin­gen wird, konn­te man in die­sem Jahr auf der größ­ten Kon­su­men­ten-Elek­tro­nik­mes­se der Welt, der CES in Las Ve­gas se­hen. Auch am Stand von In­tel gab es vie­les zu se­hen. An­ge­fan­gen vom Au­to­no­men Fah­ren, bis hin zu den Mög­lich­kei­ten, die die Vir­tu­el­le Rea­li­tät bie­tet

Weiterlesen

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.